Focus on European Funding
Christian Delles
BHF Glasgow Cardiovascular Research Centre
Institute of Cardiovascular and Medical Sciences
University of Glasgow
European Funding
Systems Biology to Identify Molecular
Targets for Vascular Disease Treatment
Proteomic prediction and Renin angiotensin
aldosterone system Inhibition prevention Of early
diabetic nephRopathy In TYpe 2 diabetic patients with
normoalbuminuria.
Identification of the MOlecular DEterminants of
established Chronic Kidney Disease
Diagnostic Imaging Strategies for Patients with Stable
Chest Pain and Intermediate Risk of Coronary Artery
Disease: Comparative Effectiveness Research of
Existing Technologies
Markers for Sub-Clinical Cardiovascular Risk
Assessemnt
HORIZON 2020
The New EU
Framework Programme for
Research and Innovation
2014-2020
Telemachos TELEMACHOU
DG Research & Innovation
European Commission
For further information
• Participant Portal
http://ec.europa.eu/research/participants/portal/desktop/en/home.html
• Helpdesk
http://ec.europa.eu/research/enquiries
• Expert evaluators needed!
http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html
• Learn more about Horizon 2020
http://ec.europa.eu/horizon2020
Thank you for your attention!
The Multiannual Financial Framework 2014-2020:
Key challenge: stabilise the financial and economic system while
taking measures to create economic opportunities
1. Smart & inclusive growth (€451 billion)
Education,
Youth, Sport
Connecting
Europe
Cohesion
Competitive
Business
SMEs
HORIZON
2020
2. Sustainable growth, natural resources (€373 billion)
3. Security and citizenship (€16 billion)
4. Global Europe (€58 billion)
5. Administration (€61.6 billion)
(figures are given in constant prices)
TOTAL
€960 billion
What is Horizon 2020
•
The new European Union programme for research and
innovation for 2014-2020
•
A budget of just over €79 billion; 30 per cent higher in real
terms than the 2007-2013 period
•
A core part of Europe 2020, Innovation Union & European
Research Area:
− Responding to the economic crisis to invest in jobs and growth
− Addressing people’s concerns about their livelihoods, safety and
environment
− Strengthening the EU’s global position in research, innovation and
technology
6
€ 79 billion from 2014 to 2020
What's new
• An integrated programme coupling research to
innovation – support from research to retail, bringing
together three separate programmes/initiatives*
• Challenge based - tackling major challenges facing EU
society, e.g. health, clean energy and transport
• Strong focus on SMEs
• Open to the rest of the world
• Major simplification - for all companies, universities,
institutes in all EU countries and beyond
⃰ The 7th Research Framework Programme (FP7), innovation aspects of
Competitiveness and Innovation Framework Programme (CIP), EU contribution to the
European Institute of Innovation and Technology (EIT)
8
Three priorities
Excellent
science
Industrial
leadership
Societal
challenges
9
Strong focus on SMEs
• In collaborative projects - 20% of total budget for societal
challenges and enabling & industrial technologies to go to SMEs
• A new SME instrument in all societal challenges and enabling &
industrial technologies (7% of relevant budgets)
• Simplification of particular benefit to SMEs (e.g. single entry point)
• Eurostars joint programme with Member States and associated
countries for research-intensive SMEs
• Access to risk finance to have a strong SME focus - (debt and
equity facilities)
10
Major Simplification
for the benefit of applicants
1. A single set of rules for all
funding under Horizon 2020
 Fewer, more flexible, funding
instruments
2. Simpler reimbursement:
1 project = 1 funding rate
 100% of the total eligible costs
(70% for innovation actions)
 Non-profit legal entities can also
receive 100% in innovation actions
 Single flat rate for indirect costs
(25% of eligible costs)
3. Faster time to grant
 Within 8 months of call deadline
Evaluation criteria
STANDARD AWARD CRITERIA
EXCELLENCE
IMPACT
 ERC frontier Research actions
 Innovation actions
QUALITY &
EFFICIENCY
OF THE ACTION
only EXCELLENCE
higher weighting for "IMPACT"
Proposal evaluated by the experts “as it is”
and not as “what could be” = no need for negotiation
Call Text
2.4.2-2: Evaluation and validation studies of clinically useful biomarkers in prevention and management of
cardiovascular diseases.
Two-stage. Existing and emerging biomarkers and related mechanisms should be exploited to improve identification, risk
assessment, clinical decision making and clinical outcomes. Cost effectiveness, safety, validity and incremental benefit over
existing risk prediction methods and life style determinants of investigated biomarkers must be demonstrated. The impact of
biomarkers on cardiovascular disease risk prediction will need to be assessed across different European populations as
they have different lifestyles (e.g. dietary patterns) and varying biomarker levels. Multidisciplinary research consortia must
use state-of-the-art translational research, epidemiological and diagnostic technology (such as imaging technology) and
knowledge.
Note: Limits on the EU financial contribution apply. These are implemented strictly as formal eligibility criteria.
Funding scheme: SME-targeted Collaborative Project.
Requested EU contribution per project: Maximum EUR 6 000 000.
One or more proposals can be selected.
Expected impact: Assessment of cardiovascular risk in individuals is complementary to public health activities that aim to
reduce the overall population risk of cardiovascular disease by promoting a healthy lifestyle (diet, exercise, avoidance of
smoking). The results of research should lead to improved cardiovascular risk prediction and contribute to the development
of personalised and predictive medicine.
Specific feature: SME-targeted research is designed to encourage SME efforts towards research and innovation. Priority
will be given to proposals demonstrating that research intensive SMEs play a leading role. The projects will be led by SMEs
with R&D capacities, but the coordinator does not need to be an SME. The expected project results should clearly be of
interest and potential benefit to SME(s).
Additional eligibility criterion: SME-targeted Collaborative Projects will only be selected for funding on the condition that
the estimated EU contribution going to SME(s) is 30-50% or more of the total estimated EU contribution for the project as a
whole. This will be assessed at the end of the negotiation, before signature of the grant agreement. Proposals not fulfilling
this criterion will not be funded.
Partners
Participant
no.
Participant
short name
Country
University of Glasgow
GLA
United
Kingdom
2
Medical University of Graz
GRA
Austria
3
Emergentec Biodevelopment GmbH
EMG
Austria
4
University of Leuven
LEU
Belgium
5
Medizinische Hochschule Hannover
MHH
Germany
6
Charité, University Berlin
CHA
Germany
7
Mosaiques Diagnostics GmbH
MOS
Germany
8
Istituto Auxologico Italiano
AUX
Italy
9
University of Milan-Bicocca
MIB
Italy
10
University of Maastricht
UMA
Netherlands
11
ACS Biomarker
ACS
Netherlands
12
Fundacíon Investigacíon Médica Applicada
FIMA
Spain
13
Fundacíon Investigacíon Biomédica, Valencia
FIHCUV
Spain
14
Randox Testing Services
RTS
United
Kingdom
15
Kite Innovation (Europe) Limited
KITE
United
Kingdom
1 (CO)
Participant organisation name
Partners
Participant
no.
Participant
short name
Country
University of Glasgow
GLA
United
Kingdom
2
Medical University of Graz
GRA
Austria
3
Emergentec Biodevelopment GmbH
EMG
Austria
4
University of Leuven
LEU
Belgium
5
Medizinische Hochschule Hannover
MHH
Germany
6
Charité, University Berlin
CHA
Germany
7
Mosaiques Diagnostics GmbH
MOS
Germany
8
Istituto Auxologico Italiano
AUX
Italy
9
University of Milan-Bicocca
MIB
Italy
10
University of Maastricht
UMA
Netherlands
11
ACS Biomarker
ACS
Netherlands
12
Fundacíon Investigacíon Médica Applicada
FIMA
Spain
13
Fundacíon Investigacíon Biomédica, Valencia
FIHCUV
Spain
14
Randox Testing Services
RTS
United
Kingdom
15
Kite Innovation (Europe) Limited
KITE
United
Kingdom
1 (CO)
Participant organisation name
Partners
Participant
no.
Participant
short name
Country
University of Glasgow
GLA
United
Kingdom
2
Medical University of Graz
GRA
Austria
3
Emergentec Biodevelopment GmbH
EMG
Austria
4
University of Leuven
LEU
Belgium
5
Medizinische Hochschule Hannover
MHH
Germany
6
Charité, University Berlin
CHA
Germany
7
Mosaiques Diagnostics GmbH
MOS
Germany
8
Istituto Auxologico Italiano
AUX
Italy
9
University of Milan-Bicocca
MIB
Italy
10
University of Maastricht
UMA
Netherlands
11
ACS Biomarker
ACS
Netherlands
12
Fundacíon Investigacíon Médica Applicada
FIMA
Spain
13
Fundacíon Investigacíon Biomédica, Valencia
FIHCUV
Spain
14
Randox Testing Services
RTS
United
Kingdom
15
Kite Innovation (Europe) Limited
KITE
United
Kingdom
1 (CO)
Participant organisation name
Key Aims
1. To validate the association of emerging biomarkers with
cardiovascular phenotypes in cross-sectional disease and
population cohorts
2. To validate emerging biomarkers as predictors of changes in
cardiovascular phenotypes and cardiovascular events in
prospective disease and population cohorts
3. Integration of emerging biomarkers reflecting different
aspects of pathophysiology with established biomarkers into
a common predictive model
4. Development of novel diagnostic test strategies to improve
clinical management of patients with cardiovascular diseases
Work Packages
WP8 and WP9
Management
WP2
Genetic markers
WP3
Proteomics
WP1
Clinical Platform
WP4
Metabolomics
WP6
Cardiac remodeling
WP5
Inflammation,
oxidative stress,
microalbuminuria
WP7
Integration
Integration
Cross sectional
Disease cohorts
Within
work packages
Longitudinal
Integration
Across
work packages
Population cohorts
Systems Medicine and Omics Technology
DNA
Genomics
mRNA
miRNAs
Transcriptomics
Protein
Proteomics
Metabolites
small molecules
Metabolomics
Systems Medicine: Data Integration
Genome
genetic variation
Transcriptome
Transcriptome
RNA profiling
miRNA profiling
Data Integration
Metabolome
Proteome
small molecules
gene products
Risk factors
Environment
Modified from Levy D, CHBPR 2010
The concept
linking processes, biomarker, and targets/drugs
slow disease progression
responders to therapy X
fast disease progression
responders to therapy Y
patient 1
patient 2
biomarker a
process A
biomarker b
process B
Goal is to identify all processes pi characterizing the phenotype which we can probe by
the biomarkers bi, from there selecting target/drug ti, di.
Challenges in Academic – Industry Collaboration
• Different language
• Different concepts of “exploitation”
• Different work patterns
• Different employment structures
• Different financial resources